After 30 years of research, pill for breast cancer approved for use
After six years of painful injections, Stephanie Walker has had enough.
Feb 8, 2023
0
4
After six years of painful injections, Stephanie Walker has had enough.
Feb 8, 2023
0
4
While it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developing new breast cancers, a new computer modeling study led by researchers at Georgetown Lombardi Comprehensive ...
Dec 1, 2022
0
2
A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise. The 18F-FES PET scan—approved by the U.S. Food and Drug Administration ...
Sep 29, 2021
0
2
In a study carried out in mice at the University of Chicago, researchers found that lasofoxifene outperformed fulvestrant, the current gold-standard drug, in reducing or preventing primary tumor growth. It also was more effective ...
May 13, 2021
0
419
Texas A&M University College of Medicine ressearchers have recently discovered that cytisine—a smoking cessation drug commonly used in Europe—reduces the loss of dopamine neurons in females. These findings provide potential ...
Mar 4, 2021
0
16
Most breast cancers utilize the female hormone estrogen to grow, so drug-induced estrogen deprivation is used as a treatment in many patients. However, cancer will recur in one-third of these patients. A research team at ...
Apr 22, 2020
0
0
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually develop drug resistance, ...
Oct 9, 2018
0
4
A new treatment for pain caused by endometriosis was approved Tuesday by U.S. regulators.
Jul 24, 2018
0
21
A University of Illinois at Chicago-developed breast cancer drug that has the potential to help women whose cancer has stopped responding to hormone therapy recently entered its first human clinical trial.
Mar 22, 2018
0
19
Researchers at UT Health San Antonio and two partner institutions are developing a new, first-in-class agent that has stopped the growth of estrogen receptor-positive (ER-positive) breast cancer in its tracks. The new agent ...
Aug 30, 2017
0
5